Clinical Trials - February 2, 2026
SynAct Pharma initiates Phase 2 study in respiratory insufficiency
SynAct Pharma has initiated a Phase 2 study (RESPIRE) with resomelagon in patients hospitalized with respiratory insufficiency due to viral infections.
Clinical Trials - January 27, 2026
Takeda’s zasocitinib meets primary and secondary endpoints in Phase 3 study
The results showed that approximately 30 percent of patients achieved complete skin clearance (PASI 100) at week 16, and that more than half reached almost complete clearance (PASI 90).
Clinical Trials - January 27, 2026
DexTech Medical’s myeloma study, completed at the end of February
The results show that all patients responded positively to the ODX treatment, with a transition from progressive disease to stable disease.
Clinical Trials - January 12, 2026
Elicera Therapeutics announces final data from its Phase I/IIa trial
Elicera Therapeutics has announced final data from its Phase I/IIa clinical trial evaluating the oncolytic virus ELC-100 in patients with advanced, end-stage neuroendocrine tumors who had exhausted all currently available therapeutic options and having progressing diseases.
Clinical Trials - January 9, 2026
Sobi to advance Gamifant in interferon-gamma-driven sepsis
Sobi has announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with observed improvement in organ dysfunction and survival.
Clinical Trials - January 8, 2026
Herantis Pharma reports encouraging data from Phase 1b trial
Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease, states the company.
